Most patients with COPD and/or asthma were able to operate their dry powder inhalers correctly and reported that they were not difficult to use, according to two GlaxoSmithKline-sponsored studies presented at ACAAI 2016.

Researchers evaluated a placebo version of the Glaxo multi-dose dry powder inhaler with twin-strip technology in patients with asthma who had not used a dry powder inhaler before their participation in the study and in patients with COPD who had not used an inhaler during the 6 months prior to enrolling in the study.

At the end of the 28-day study period, almost all the patients recruited for the study were able to demonstrate correct use of the placebo study inhaler within a single attempt. Among patients who demonstrated correct inhaler use at study end, the majority rated the inhaler as “easy” or “very easy” to use.